Keywords: UK, NICE, Roche, MabThera, Follicular lymphoma

UK’s NICE backs Roche’s MabThera for first-line maintenance of follicular lymphoma

Article | 24 May 2011

Print This

The UK’s drug rationing watchdog the National Institute for Health and Clinical Excellence (NICE) today issued a positive ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in